全文获取类型
收费全文 | 221679篇 |
免费 | 40328篇 |
国内免费 | 9737篇 |
专业分类
耳鼻咽喉 | 3636篇 |
儿科学 | 3772篇 |
妇产科学 | 3244篇 |
基础医学 | 15824篇 |
口腔科学 | 7180篇 |
临床医学 | 40624篇 |
内科学 | 41371篇 |
皮肤病学 | 4523篇 |
神经病学 | 17868篇 |
特种医学 | 8816篇 |
外国民族医学 | 59篇 |
外科学 | 32086篇 |
综合类 | 24643篇 |
现状与发展 | 71篇 |
一般理论 | 7篇 |
预防医学 | 22510篇 |
眼科学 | 5152篇 |
药学 | 14467篇 |
93篇 | |
中国医学 | 7508篇 |
肿瘤学 | 18290篇 |
出版年
2024年 | 1144篇 |
2023年 | 6700篇 |
2022年 | 5425篇 |
2021年 | 8357篇 |
2020年 | 9693篇 |
2019年 | 5685篇 |
2018年 | 10569篇 |
2017年 | 11040篇 |
2016年 | 11466篇 |
2015年 | 13576篇 |
2014年 | 17427篇 |
2013年 | 18934篇 |
2012年 | 14110篇 |
2011年 | 14392篇 |
2010年 | 14488篇 |
2009年 | 15393篇 |
2008年 | 11078篇 |
2007年 | 9728篇 |
2006年 | 10553篇 |
2005年 | 8397篇 |
2004年 | 5971篇 |
2003年 | 5579篇 |
2002年 | 4842篇 |
2001年 | 4869篇 |
2000年 | 3629篇 |
1999年 | 3951篇 |
1998年 | 3409篇 |
1997年 | 3222篇 |
1996年 | 2908篇 |
1995年 | 2515篇 |
1994年 | 1880篇 |
1993年 | 1391篇 |
1992年 | 1389篇 |
1991年 | 1146篇 |
1990年 | 951篇 |
1989年 | 890篇 |
1988年 | 858篇 |
1987年 | 670篇 |
1986年 | 596篇 |
1985年 | 500篇 |
1984年 | 354篇 |
1983年 | 369篇 |
1982年 | 280篇 |
1981年 | 241篇 |
1980年 | 143篇 |
1979年 | 115篇 |
1978年 | 145篇 |
1977年 | 135篇 |
1976年 | 89篇 |
1974年 | 84篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
11.
目的 探讨右美托咪定联合综合体温保护对腔镜手术治疗老年恶性肿瘤患者苏醒期质量及免疫功能的影响。方法 选择择期行腔镜手术治疗的老年恶性肿瘤患者90例,随机均分为3组:对照组(C组)、体温保护组(T组)和体温保护联合右美托咪定组(T-D组),每组30例。C组常规体温保护,T组和T-D组综合体温保护;T-D组麻醉诱导前10 min泵注右美托咪定0.5 μg/kg。记录3组患者麻醉诱导开始时(T0)、手术开始30 min(T1)、60 min(T2)、90 min(T3)、120 min(T4)以及手术结束时(T5)的鼻咽温度;于T0、术后2 h(T6)、24 h(T7)和48 h(T8)时抽取静脉血标本,测定T淋巴细胞亚群(CD3+、CD4+和CD8+)和自然杀伤细胞(NK cell)水平;记录患者术中麻醉药物用量及苏醒期质量指标。结果 与T0比较,C组T2~T5时点鼻咽温度均明显降低(P < 0.05);与C组比较,T组和T-D组T2~T5时点鼻咽温度明显升高(P < 0.05)。与T0时点比较,C组、T组和T-D组T6、T7和T8时点CD3+和NK cell活性均明显降低(P < 0.05);C组在T6、T7和T8时点,T组和T-D组在T6和T7时点,CD4+活性均明显降低(P < 0.05)。与C组比较,T组和T-D组T6和T7时点CD3+细胞活性均明显升高(P < 0.05);T组在T7时点,T-D组在T6和T7时点,CD4+细胞活性均明显升高(P < 0.05);T组在T7时点,T-D组在T6、T7和T8时点,NK cell活性均明显升高(P < 0.05)。结论 采用体温保护措施联合右美托咪定能够维持老年恶性肿瘤患者的体温稳定,减少围手术期意外低体温(IPH)的发生,并有效提高患者苏醒期质量,减轻免疫抑制程度,加速患者早期恢复。 相似文献
12.
13.
14.
15.
16.
Two Janus-associated kinase inhibitors (JAKi) (initially ruxolitinib and, more recently, fedratinib) have been approved as treatment options for patients who have intermediate-risk and high-risk myelofibrosis (MF), with pivotal trials demonstrating improvements in spleen volume, disease symptoms, and quality of life. At the same time, however, clinical trial experiences with JAKi agents in MF have demonstrated a high frequency of discontinuations because of adverse events or progressive disease. In addition, overall survival benefits and clinical and molecular predictors of response have not been established in this population, for which the disease burden is high and treatment options are limited. Consistently poor outcomes have been documented after JAKi discontinuation, with survival durations after ruxolitinib ranging from 11 to 16 months across several studies. To address such a high unmet therapeutic need, various non-JAKi agents are being actively explored (in combination with ruxolitinib in first-line or salvage settings and/or as monotherapy in JAKi-pretreated patients) in phase 3 clinical trials, including pelabresib (a bromodomain and extraterminal domain inhibitor), navitoclax (a B-cell lymphoma 2/B-cell lymphoma 2-xL inhibitor), parsaclisib (a phosphoinositide 3-kinase inhibitor), navtemadlin (formerly KRT-232; a murine double-minute chromosome 2 inhibitor), and imetelstat (a telomerase inhibitor). The breadth of data expected from these trials will provide insight into the ability of non-JAKi treatments to modify the natural history of MF. 相似文献
17.
Raymond J. Chan RN PhD Vivienne E. Milch MBBS MHPol Fiona Crawford-Williams PhD Oluwaseyifunmi Andi Agbejule BRadTherapy Ria Joseph MNutrDiet Jolyn Johal BND Narayanee Dick BSc Matthew P. Wallen PhD Julie Ratcliffe PhD Anupriya Agarwal MBBS Larissa Nekhlyudov MD Matthew Tieu PhD Manaf Al-Momani BPharm Scott Turnbull PhD Rahul Sathiaraj MPH Dorothy Keefe MBBS MD Nicolas H. Hart PhD 《CA: a cancer journal for clinicians》2023,73(6):565-589
Patient navigation is a strategy for overcoming barriers to reduce disparities and to improve access and outcomes. The aim of this umbrella review was to identify, critically appraise, synthesize, and present the best available evidence to inform policy and planning regarding patient navigation across the cancer continuum. Systematic reviews examining navigation in cancer care were identified in the Cochrane Central Register of Controlled Trials (CENTRAL), PubMed, Embase, Cumulative Index of Nursing and Allied Health (CINAHL), Epistemonikos, and Prospective Register of Systematic Reviews (PROSPERO) databases and in the gray literature from January 1, 2012, to April 19, 2022. Data were screened, extracted, and appraised independently by two authors. The JBI Critical Appraisal Checklist for Systematic Review and Research Syntheses was used for quality appraisal. Emerging literature up to May 25, 2022, was also explored to capture primary research published beyond the coverage of included systematic reviews. Of the 2062 unique records identified, 61 systematic reviews were included. Fifty-four reviews were quantitative or mixed-methods reviews, reporting on the effectiveness of cancer patient navigation, including 12 reviews reporting costs or cost-effectiveness outcomes. Seven qualitative reviews explored navigation needs, barriers, and experiences. In addition, 53 primary studies published since 2021 were included. Patient navigation is effective in improving participation in cancer screening and reducing the time from screening to diagnosis and from diagnosis to treatment initiation. Emerging evidence suggests that patient navigation improves quality of life and patient satisfaction with care in the survivorship phase and reduces hospital readmission in the active treatment and survivorship care phases. Palliative care data were extremely limited. Economic evaluations from the United States suggest the potential cost-effectiveness of navigation in screening programs. 相似文献
18.
19.